Clinical publication reports that SFDI measures dermal microcirculatory changes prior to ulcer formation

Irvine, CA—March 8, 2021—In a recent case series published in the BMJ Open Diabetes Research & Care journal, a clinical research team lead by Dr. David Armstrong at USC measured the oxygenation and perfusion of neuropathic and neuroischemic ulcers with SFDI. The case series reported that unique signatures in the visual maps of oxygenation and perfusion preceded visible breakdown. In one case, the patient had focal changes in circulation 3 months before skin breakdown. The case series also noted that biomarker trends differed based on the etiology (i.e. Neuroischemic vs. neuropathic) of ulcer that formed and claimed that this was the first manuscript describing these unique patterns using SFDI.

 

Knowledge of the etiology of an ulcer can aide clinicians with treatment decisions that can help clinicians with evaluating therapy efficacy with the intent of reducing healing times. The research article noted that with further research, SFDI data could be used with predictive modeling from images to identify tissue at risk and enable earlier and more focused prophylactic treatment against foot ulcers.

 

Publication link here: https://drc.bmj.com/content/8/2/e001815

 

About Modulim

 

Modulim is a privately held medical device company founded by the inventors of SFDI at the University of California Irvine with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Its mission is to deliver transformative optical solutions that help people live healthier, longer lives. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Clarifi Imaging System is an FDA cleared and CE Marked product. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK. Clarifi is a registered trademark of Modulated Imaging (dba Modulim).

 

Contacts

Gary Marston

VP Sales and Marketing

(949) 825-5075

gmarston@modulim.com